The CTGF -945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetes

7Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The -945GC polymorphism (rs6918698) in the connective tissue growth factor gene promoter (CTGF/CCN-2) has been associated with end organ damage in systemic sclerosis. Because CTGF is important in progression of diabetic kidney disease, we investigated whether the -945GC polymorphism is associated with plasma CTGF level and outcome in type 1 diabetes. The study cohort consisted of 448 diabetic nephropathy patients and 419 normoalbuminuric diabetic patients with complete data concerning renal function and cardiovascular characteristics. Genomic DNA was genotyped by a QPCR-based SNP assay. We observed no relation between the -945GC polymorphism and plasma CTGF level, and the genotype frequencies were not different in nephropathy patients vs. normoalbuminuric controls. General and cardiovascular mortality, and renal function decline was similar in patients with CC, CG or GG genotypes. In conclusion, the -945GC SNP does not affect plasma CTGF levels, incidence and prognosis of diabetic nephropathy, and cardiovascular outcome. © 2011 Dendooven et al; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Dendooven, A., Nguyen, T. Q., Brosens, L., Li, D., Tarnow, L., Parving, H. H., … Goldschmeding, R. (2011). The CTGF -945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetes. Journal of Negative Results in BioMedicine, 10(1). https://doi.org/10.1186/1477-5751-10-4

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free